PMID- 34186365
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20211230
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 15
IP  - 4
DP  - 2021 Jul-Aug
TI  - Effect of anti-inflammatory therapy on major cardiovascular events in patients 
      with diabetes: A meta-analysis.
PG  - 102164
LID - S1871-4021(21)00182-X [pii]
LID - 10.1016/j.dsx.2021.06.001 [doi]
AB  - BACKGROUND: In patients with coronary artery disease anti-inflammatory drugs have 
      been shown to be effective in reducing cardiovascular events. The effect of this 
      intervention in the population with type 2 diabetes mellitus (T2DM) is poorly 
      explored. The main objective of this study was to evaluate the effect of 
      anti-inflammatory therapy on the incidence of major cardiovascular events (MACE) 
      in patients with T2DM. METHODS: A meta-analysis of randomized studies that 
      evaluated the use of anti-inflammatory therapy in patients with T2DM and reported 
      MACE was performed, after searching the PubMed/MEDLINE, Embase, Scielo, Google 
      Scholar and Cochrane Controlled Trials databases. A fixed or random effects 
      models were used. RESULTS: Five studies were selected for the analysis (2075 
      subjects in the anti-inflammatory therapy arm and 2490 patients in the 
      placebo/control arm). All studies included patients with T2DM and history of 
      coronary artery disease. Four studies evaluated the use of colchicine and one of 
      them canakinumab. The use of anti-inflammatory therapy was associated with a 
      lower risk of MACE (HR: 0.80; 95% CI, 0.69-0.93; I(2) = 24%). The sensitivity 
      analysis shows that the results are robust. CONCLUSION: This meta-analysis 
      demonstrated that the use of anti-inflammatory therapy in patients with T2DM and 
      atherosclerotic cardiovascular disease was associated with reduced risk of MACE. 
      These results suggest the need to consider the inflammatory pathway as a 
      potential therapeutic target in patients with T2DM.
CI  - Copyright (c) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.
FAU - Masson, Walter
AU  - Masson W
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Peron 4190, Buenos 
      Aires, Argentina. Electronic address: walter.masson@hospitalitaliano.org.ar.
FAU - Lobo, Martin
AU  - Lobo M
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Hospital Militar Campo de Mayo, Tte. Gral. Ricchieri S/N, Buenos Aires, 
      Argentina.
FAU - Barbagelata, Leandro
AU  - Barbagelata L
AD  - Cardiology Department, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo 
      Peron 4190, Buenos Aires, Argentina.
FAU - Lavalle-Cobo, Augusto
AU  - Lavalle-Cobo A
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina; Cardiology Department, 
      Sanatorio Finochietto, Av. Cordoba 2678, Buenos Aires, Argentina.
FAU - Molinero, Graciela
AU  - Molinero G
AD  - Council of Epidemiology and Cardiovascular Prevention, Argentine Society of 
      Cardiology, Azcuenaga 980, Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210605
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (IL1B protein, human)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (NLRP3 protein, human)
SB  - IM
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Cardiovascular Diseases/*epidemiology
MH  - Diabetes Mellitus, Type 2/*epidemiology
MH  - Humans
MH  - Interleukin-1beta
MH  - Interleukin-6
MH  - NLR Family, Pyrin Domain-Containing 3 Protein
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Anti-Inflammatory therapy
OT  - Canakinumab
OT  - Colchicine
OT  - Diabetes
OT  - Major cardiovascular events
COIS- Declaration of competing interest The authors declare that they have no conflict 
      of interest.
EDAT- 2021/06/30 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/06/29 20:20
PHST- 2021/04/07 00:00 [received]
PHST- 2021/05/04 00:00 [revised]
PHST- 2021/06/02 00:00 [accepted]
PHST- 2021/06/30 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
PHST- 2021/06/29 20:20 [entrez]
AID - S1871-4021(21)00182-X [pii]
AID - 10.1016/j.dsx.2021.06.001 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102164. doi: 10.1016/j.dsx.2021.06.001. 
      Epub 2021 Jun 5.